Management of moderate to severe psoriasis in patients with metabolic comorbidities

Frontiers in Medicine

Volumn 2, Issue JAN, 2015, Pages

  Gisondi, Paolo ^a   Galvan, Arturo ^a   Idolazzi, Luca ^b   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Biological therapies; Comorbidities; Conventional therapies; Psoriasis

Indexed keywords

EID: 85062631875     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00001     Document Type: Short Survey

References (51)

1. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 44:1341-8. doi: 10.1038/ng.2467
2. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol (2010) 130:1213-26. doi:10.1038/jid.2009.319
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature (2007) 445:866-73. doi:10.1038/nature05663
4. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med (2009) 361:496-509. doi:10.1056/NEJMra0804595
5. Gisondi P, Girolomoni G. Impact of TNF-a antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol (2013) 148:243-8
6. Gisondi P, Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr (2009) 100(Suppl 2):14-21. doi:10.1016/S0001-7310(09)73373-3
7. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes (2012) 2:e54. doi:10.1038/nutd.2012.26
8. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' health study II. Arch Intern Med (2007) 13(167):1670-5. doi:10.1001/archinte.167.15.1670
9. Paller AS, Mercy K, Kwasny MJ, Choon SE, Cordoro KM, Girolomoni G, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol (2013) 149:166-76. doi:10.1001/jamadermatol.2013.1078
10. Soltani-Arabshahi R, Wong B, Feng B-J, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol (2010) 146:721-6. doi:10.1001/archdermatol.2010.141
11. Davidovici BB, Sattar N, Prinz JC, Jörg PC, Puig L, Emery P, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 130:1785-96. doi:10.1038/jid.2010.103
12. Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martinez-Camblor P, Maldonado-Seral C, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol (2013) 169:783-93. doi:10.1111/bjd.12473
13. Buerger C, Richter B, Woth K, Salgo R, Malisiewicz B, Diehl S, et al. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol (2012) 132:2206-14. doi:10.1038/jid.2012.123
14. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol (2007) 157:68-73. doi:10.1111/j.1365-2133.2007.07986.x
15. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol (2013) 68:654-62. doi:10.1016/j.jaad.2012.08.015
16. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab (2013) 98:483-95. doi:10.1210/jc.2012-3093
17. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 51:758-64. doi:10.1016/j.jhep.2009.04.020
18. Van der Voort EAM, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HLA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol (2014) 70:517-24. doi:10.1016/j.jaad.2013.10.044
19. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 363:1341-50. doi:10.1056/NEJMra0912063
20. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud P-A, Aractingi S, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol (2010) 24(Suppl 2):23-30. doi:10.1111/j.1468-3083.2009.03564.x
21. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol (2013) 133:2340-6. doi:10.1038/jid.2013.149
22. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc (2013) 2(2):e000062. doi:10.1161/JAHA.113.000062
23. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med (2011) 124:.e1-6. doi:10.1016/j.amjmed.2011.03.028
24. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ (2013) 347:f5961. doi:10.1136/bmj.f5961
25. Lu Y, Chen H, Nikamo P, Qi Low H, Helms C, Seielstad M, et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol (2013) 133:836-9. doi:10.1038/jid.2012.366
26. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol (2013) 168:749-55. doi:10.1111/bjd.12118
27. Rosenberg P, Urwitz H, Johannesson A, Ros A-M, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol (2007) 46:1111-8. doi:10.1016/j.jhep.2007.01.024
28. Lynch M, Higgins E, McCormick PA, Kirby B, Nolan N, Rogers S, et al. The use of transient elastography and fibrotest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatol (2014) 150(8):856-62. doi:10.1001/jamadermatol.2013.9336
29. Balato N, Patruno C, Napolitano M, Patrí A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging (2014) 31:233-8. doi:10.1007/s40266-014-0156-6
30. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol (2013) 27:e30-41. doi:10.1111/j.1468-3083.2012.04450.x
31. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 80:565-81. doi:10.1016/j.clpt.2006.09.003
32. Chappe SG, Roenigk HH, Miller AJ, Beeaff DE, Tyrpin L. The effect of photochemotherapy on the cardiovascular system. J Am Acad Dermatol (1981) 4:561-6. doi:10.1016/S0190-9622(81)70057-4
33. Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol (2011) 21:916-20. doi:10.1684/ejd.2011.1548
34. Renzo LDI, Saraceno R, Schipani C, Rizzo M, Bianchi A, Noce A, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-a treatment. Dermatol Ther (2011) 24:446-51. doi:10.1111/j.1529-8019.2011.01439.x
35. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol (2008) 22:341-4. doi:10.1111/j.1468-3083.2007.02429.x
36. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol (2013) 168:1124-7. doi:10.1111/bjd.12235
37. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther (2012) 14:141. doi:10.1186/ar3874
38. Campanati A, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol (2013) 48:839-46. doi:10.1007/s00535-012-0678-9
39. Martínez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res (2007) 299:461-5. doi:10.1007/s00403-007-0784-3
40. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol (2007) 20:731-6
41. Kofoed K, Clemmensen A, Mikkelsen UR, Simonsen L, Andersen O, Gniadecki R. Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis. Arch Dermatol (2012) 148:1089-91. doi:10.1001/archdermatol.2012.1753
42. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 305:2525-31. doi:10.1001/jama.2011.878
43. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol (2013) 68:863-5. doi:10.1016/j.jaad.2013.01.011
44. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol (2012) 11:1210-7
45. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol (1986) 15:1007-22. doi:10.1016/S0190-9622(86)70265-X
46. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr (2008) 88:1242-7
47. Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol (2014) 170:634-42. doi:10.1111/bjd.12735
48. Jensen P, Zachariae C, Christensen R, Geiker NRW, Schaadt BK, Stender S, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol (2013) 149:795-801. doi:10.1001/jamadermatol.2013.722
49. Kinahan CE, Mazloom S, Fernandez AP. Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study. Br J Dermatol (2014). doi:10.1111/bjd.13359
50. Torres T, Alexandre JM, Mendonça D, Vasconcelos C, Silva BM, Selores M. Levels of physical activity in patients with severe psoriasis: a cross-sectional questionnaire study. Am J Clin Dermatol (2014) 15:129-35. doi:10.1007/s40257-014-0061-0
51. Balato N, Megna M, Palmisano F, Patruno C, Napolitano M, Scalvenzi M, et al. Psoriasis and sport: a new ally? J Eur Acad Dermatol Venereol (2014). doi:10.1111/jdv.12607